GeneBioTech Co. Ltd (086060) — Cash Flow Quality Index
GeneBioTech Co. Ltd (086060) has a Cash Flow Quality Index of 3.92x as of September 2025. Operating cash flow of ₩3.87 Billion exceeds net income of ₩986.50 Million, indicating high earnings quality where cash backs reported profits. Explore investment intensity of GeneBioTech Co. Ltd to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
GeneBioTech Co. Ltd Cash Flow Quality Index (2009–2024)
Historical Cash Flow Quality Index for GeneBioTech Co. Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check GeneBioTech Co. Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for GeneBioTech Co. Ltd (2009–2024)
Year-by-year earnings quality comparison for GeneBioTech Co. Ltd. For live market cap and the full company financial profile, see GeneBioTech Co. Ltd (086060) market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.16x | ₩-463.87 Million | ₩2.87 Billion | ▼ -105.7% |
| 2023 | 2.84x | ₩7.37 Billion | ₩2.59 Billion | ▲ +217.7% |
| 2022 | -2.42x | ₩-3.68 Billion | ₩1.52 Billion | ▲ +23.7% |
| 2019 | -3.17x | ₩-2.68 Billion | ₩846.78 Million | ▼ -242.7% |
| 2018 | 2.22x | ₩5.96 Billion | ₩2.68 Billion | ▲ +309.5% |
| 2017 | 0.54x | ₩1.13 Billion | ₩2.09 Billion | ▼ -74.1% |
| 2016 | 2.10x | ₩5.31 Billion | ₩2.53 Billion | ▼ -53.0% |
| 2015 | 4.46x | ₩2.61 Billion | ₩583.71 Million | ▲ +125.9% |
| 2014 | 1.98x | ₩2.15 Billion | ₩1.09 Billion | ▼ -83.1% |
| 2013 | 11.66x | ₩2.38 Billion | ₩203.94 Million | ▲ +152.7% |
| 2011 | 4.61x | ₩2.53 Billion | ₩547.78 Million | ▲ +322.2% |
| 2010 | 1.09x | ₩1.17 Billion | ₩1.07 Billion | ▼ -71.0% |
| 2009 | 3.77x | ₩2.68 Billion | ₩711.60 Million | — |